The TRANEXAMIC ACID TABLETS is a the manufacturer industrial component. Key specifications include administration: ORAL, primary_container_type: BOTTLE, primary_container_content_quantity: 30.0 TABLETS, active_medicament_medicinal_strength: 650.0 MILLIGRAMS TRANEXAMIC ACID ACTIVE INGREDIENT, part_name_assigned_by_controlling_agency: TRANEXAMIC ACID TABLETS 650MG 30'S. This product is currently in active production with full OEM support.
This part is cataloged in the Federal Logistics Information System (FLIS) under NSN 6505-01-718-5243, indicating validated use in U.S. government and defense logistics supply chains. Available through authorized enterprise resellers and TPM (Third Party Maintenance) channels.
Verify compatibility with your specific system configuration before ordering.
| administration | ORAL |
| primary_container_type | BOTTLE |
| primary_container_content_quantity | 30.0 TABLETS |
| active_medicament_medicinal_strength | 650.0 MILLIGRAMS TRANEXAMIC ACID ACTIVE INGREDIENT |
| part_name_assigned_by_controlling_agency | TRANEXAMIC ACID TABLETS 650MG 30'S |
| NSN | 6505-01-718-5243 |
| PRIMARY CONTAINER TYPE | BOTTLE |
| PART NAME ASSIGNED BY CONTROLLING AGENCY | TRANEXAMIC ACID TABLETS 650MG 30'S |
| ADMINISTRATION | ORAL |
| PRIMARY CONTAINER CONTENT QUANTITY | 30.0 TABLETS |
| ACTIVE MEDICAMENT MEDICINAL STRENGTH | 650.0 MILLIGRAMS TRANEXAMIC ACID ACTIVE INGREDIENT |
| SPECIAL FEATURES | TRANEXAMIC ACID USP 650MG TABLETS, 30 PER BOTTLE. ANTIFIBRINOLYTIC AGENT INDICATED FOR THE TREATMENT OF CYCLIC HEAVY MENSTRUAL BLEEDING IN FEMALES OFREPRODUCTIVE POTENTIAL. STORE AT ROOM TEMPERATURE 25 C (77 F); EXCURSIONS PERMITTED TO 15-30 C (59-86 F). (SEE USP CONTROLLED ROOM TEMPERATURE). |